
FDA Rejects Ivonescimab Application for Advanced Lung Cancer Treatment
The US Food and Drug Administration declined to approve Summit Therapeutics' application for ivonescimab combined with chemotherapy for a specific group of patients with advanced EGFR-mutated non-small cell lung cancer. The main concern was the lack of statistically significant improvement in overall survival























